{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:37:34Z","timestamp":1790116654918,"version":"4.0.1"},"reference-count":35,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Victorian Government\u2019s Operational Infrastructure Support Program","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Statins are the first-line lipid-lowering therapy for reducing cardiovascular disease (CVD) risk. A plasma lipid ratio of two phospholipids, PI(36:2) and PC(18:0_20:4), was previously identified to explain 58% of the relative CVD risk reduction associated with pravastatin, independent of a change in low-density lipoprotein-cholesterol. This ratio may be a potential biomarker for the treatment effect of statins; however, the underlying mechanisms linking this ratio to CVD risk remain unclear. In this study, we investigated the effect of altered cholesterol conditions on the lipidome of cultured human liver cells (Hep3B). Hep3B cells were treated with simvastatin (5 \u03bcM), cyclodextrin (20 mg\/mL) or cholesterol-loaded cyclodextrin (20 mg\/mL) for 48 h and their lipidomes were examined. Induction of a low-cholesterol environment via simvastatin or cyclodextrin was associated with elevated levels of lipids containing arachidonic acid and decreases in phosphatidylinositol species and the PI(36:2)\/PC(18:0_20:4) ratio. Conversely, increasing cholesterol levels via cholesterol-loaded cyclodextrin resulted in reciprocal regulation of these lipid parameters. Expression of genes involved in cholesterol and fatty acid synthesis supported the lipidomics data. These findings demonstrate that the PI(36:2)\/PC(18:0_20:4) ratio responds to changes in intracellular cholesterol abundance per se, likely through a flux of the n-6 fatty acid pathway and altered phosphatidylinositol synthesis. These findings support this ratio as a potential marker for CVD risk reduction and may be useful in monitoring treatment response.<\/jats:p>","DOI":"10.3390\/metabo11060340","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T13:14:21Z","timestamp":1621948461000},"page":"340","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Impact of Simvastatin on Lipidomic Markers of Cardiovascular Risk in Human Liver Cells Is Secondary to the Modulation of Intracellular Cholesterol"],"prefix":"10.3390","volume":"11","author":[{"given":"Yvette L.","family":"Schooneveldt","sequence":"first","affiliation":[{"name":"Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia"},{"name":"Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC 3004, Australia"},{"name":"Lipid Metabolism & Cardiometabolic Disease Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6050-1259","authenticated-orcid":false,"given":"Corey","family":"Giles","sequence":"additional","affiliation":[{"name":"Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia"},{"name":"Baker Department of Cardiometabolic Health, University of Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Keating","sequence":"additional","affiliation":[{"name":"Lipid Metabolism & Cardiometabolic Disease Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie A.","family":"Mellett","sequence":"additional","affiliation":[{"name":"Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron W.","family":"Jurrjens","sequence":"additional","affiliation":[{"name":"Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia"},{"name":"Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC 3004, Australia"},{"name":"Lipid Metabolism & Cardiometabolic Disease Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudip","family":"Paul","sequence":"additional","affiliation":[{"name":"Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia"},{"name":"Baker Department of Cardiometabolic Health, University of Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C.","family":"Calkin","sequence":"additional","affiliation":[{"name":"Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC 3004, Australia"},{"name":"Lipid Metabolism & Cardiometabolic Disease Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia"},{"name":"Baker Department of Cardiometabolic Health, University of Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2593-4665","authenticated-orcid":false,"given":"Peter J.","family":"Meikle","sequence":"additional","affiliation":[{"name":"Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia"},{"name":"Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC 3004, Australia"},{"name":"Baker Department of Cardiometabolic Health, University of Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic Effects of Statins","volume":"45","author":"Liao","year":"2004","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ballantyne, C.M., Raichlen, J.S., Nicholls, S.J., Erbel, R., Tardif, J.C., Brener, S.J., Cain, V.A., and Nissen, S.E. (2008). Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography. Circulation, 117.","DOI":"10.1161\/CIRCULATIONAHA.108.773747"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0002-9149(99)80476-7","article-title":"Lipid-lowering interventions in angiographic trials","volume":"76","author":"Rossouw","year":"1995","journal-title":"Am. J. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","article-title":"A systematic review and meta-analysis on the therapeutic equivalence of statins","volume":"35","author":"Weng","year":"2010","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Scandinavian Simvastatin Survival Study Group (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383\u20131389.","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med., 339, 1349\u20131357.","DOI":"10.1056\/NEJM199811053391902"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia. West of Scotland coronary prevention study group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_9","first-page":"129","article-title":"The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals","volume":"7","author":"Kureishi","year":"2001","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0021-9150(00)00468-8","article-title":"Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits","volume":"154","author":"Rikitake","year":"2001","journal-title":"Atherosclerosis"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1161\/01.ATV.21.5.804","article-title":"3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: Balance between transcriptional and posttranscriptional regulation","volume":"21","author":"Raposo","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e128438","DOI":"10.1172\/jci.insight.128438","article-title":"Changes in plasma lipids predict pravastatin efficacy in secondary prevention","volume":"4","author":"Jayawardana","year":"2019","journal-title":"JCI Insight"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2147\/VHRM.S1653","article-title":"Clinical efficacy and safety of statins in managing cardiovascular risk","volume":"4","author":"Kapur","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lydic, A.T., and Goo, Y.H. (2018). Lipidomics unveils the complexity of the lipidome in metabolic diseases. Clin. Transl. Med., 7.","DOI":"10.1186\/s40169-018-0182-9"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0022-2275(20)32454-8","article-title":"Plasmalogen status influences docosahexaenoic acid levels in a macrophage cell line. Insights using ether lipid-deficient variants","volume":"40","author":"Gaposchkin","year":"1999","journal-title":"J. Lipid Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1073\/pnas.86.10.3479","article-title":"Plasmenylethanolamine is the major storage depot for arachidonic acid in rabbit vascular smooth muscle and is rapidly hydrolyzed after angiotensin II stimulation","volume":"86","author":"Ford","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/0003-9861(89)90146-X","article-title":"Effects of eicosapentaenoic and docosahexaenoic acid supplements on phospholipid composition and plasmalogen biosynthesis in P388D1 cells","volume":"269","author":"Blank","year":"1989","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1054\/plef.2001.0285","article-title":"Essential fatty acids as possible mediators of the actions of statins","volume":"65","author":"Das","year":"2001","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1253\/circj.CJ-10-0939","article-title":"Beneficial actions of statins in the reduction of atrial fibrillation and stabilization and regression of coronary plaques: But how and why?","volume":"75","author":"Das","year":"2011","journal-title":"Circ. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1172\/JCI116945","article-title":"Lovastatin increases arachidonic acid levels and stimulates thromboxane synthesis in human liver and monocytic cell lines","volume":"93","author":"Hrboticky","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3945\/ajcn.111.012054","article-title":"Fatty acids in the de novo lipogenesis pathway and risk of coronary heart disease. The Cardiovascular Health Study","volume":"94","author":"Wu","year":"2011","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1194\/jlr.M600299-JLR200","article-title":"Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death","volume":"47","author":"Borradaile","year":"2006","journal-title":"J. Lipid Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/CS20040140","article-title":"Non-esterified fatty acids impair endothelium-dependent vasodilation in rat mesenteric resistance vessels","volume":"107","author":"Sainsbury","year":"2004","journal-title":"Clin. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1161\/ATVBAHA.109.201681","article-title":"Nutrient modification of the innate immune response: A novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation","volume":"30","author":"Schwartz","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1096\/fj.08-125674","article-title":"Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: A role for resolvins and protectins","volume":"23","author":"Horrill","year":"2009","journal-title":"FASEB J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/S0022-2275(20)34940-3","article-title":"Use of cyclodextrins for manipulating cellular cholesterol content","volume":"38","author":"Christian","year":"1997","journal-title":"J. Lipid Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"29422","DOI":"10.1074\/jbc.270.49.29422","article-title":"Hairpin Orientation of Sterol Regulatory Element-binding Protein-2 in Cell Membranes as Determined by Protease Protection","volume":"270","author":"Hua","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e28534","DOI":"10.1371\/journal.pone.0028534","article-title":"Statins Promote the Regression of Atherosclerosis via Activation of the CCR7-Dependent Emigration Pathway in Macrophages","volume":"6","author":"Feig","year":"2011","journal-title":"PLoS ONE"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1194\/jlr.M800383-JLR200","article-title":"Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice","volume":"50","author":"Moon","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_30","first-page":"97","article-title":"Delta5 Desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPAR\u03b1, in THP-1 cell","volume":"571","author":"Ghezzi","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/hep.29039","article-title":"Protective role of endogenous plasmalogens against hepatic steatosis and steatohepatitis","volume":"66","author":"Jang","year":"2017","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0003-2697(89)90101-2","article-title":"Protein measurement using bicinchoninic acid: Elimination of interfering substances","volume":"180","author":"Brown","year":"1989","journal-title":"Anal. Biochem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1194\/jlr.P035808","article-title":"Plasma lipid profiling in a large population-based cohort","volume":"54","author":"Weir","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.chembiol.2018.10.008","article-title":"High-Throughput Plasma Lipidomics: Detailed Mapping of the Associations with Cardiometabolic Risk Factors","volume":"26","author":"Huynh","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B (Methodol.)"}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/11\/6\/340\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:07:29Z","timestamp":1760162849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/11\/6\/340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["metabo11060340"],"URL":"https:\/\/doi.org\/10.3390\/metabo11060340","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]}}}